LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Clinical Trials Registration NCT02263326. Click to show full abstract

Clinical Trials Registration NCT02263326.

Keywords: human immunodeficiency; maintains human; plus lamivudine; immunodeficiency virus; lamivudine maintains; dolutegravir plus

Journal Title: Clinical Infectious Diseases
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended


                Click one of the above tabs to view related content.